NCT05355051招募中2 期
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- To assess the overall response rate (ORR)
研究概览
简要总结
This study is a Phase II single-center clinical trial designed to assess the efficacy, safety, and tolerability of pembrolizumab in combination with the 7-day regimen of azacitidine for the treatment of relapsed/refractory HL.
详细描述
OBJECTIVES:
Primary Objectives:
• To assess the overall response rate (ORR) of Pembrolizumab in combination with azacitidine in patients with relapsed or progressed classical Hodgkin lymphoma (HL).
Secondary Objectives:
- To assess the duration of response (DOR), relapse-free survival (RFS), and overall survival (OS) of patients with refractory/relapsed HL treated with this combination.
- To assess the safety of Pembrolizumab in combination with azacitidine in children with refractory/relapsed HL.
- To assess the proportion of patients who proceed to stem cell transplantation upon achieving response with the combination of Pembrolizumab and Azacitidine regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •HL patients with relapse or progression. Prior checkpoint inhibitors will be allowed
- •AML patients with relapse or progression. Patients may receive cytoreduction prior to enrollment for patients with rapidly proliferative disease before the start of study therapy, as needed, for clinical benefit and after discussion with the PI. Concurrent therapy for central nervous system (CNS) prophylaxis or continuation of therapy for controlled CNS disease is permitted
- •Patients with relapsed HL involving extranodal sites
- •HL patients who are not regarded as a candidate for high-dose, conventional chemotherapy
- •Age of enrollment: Minimum age 1 year. No maximum age, study will include anyone in the pediatric/adolescent center
- •Eastern Cooperative Oncology Group (ECOG) performance status =< 3 or Lansky performance status >= 50
- •Adequate renal function per age unless related to the disease
- •Adequate hepatic function including total bilirubin < 2x upper limit of normal (ULN) unless increase is due to Gilbert's disease, and AST < 3x ULN unless considered due to lymphoma involvement.
- •Provision of written informed consent or assent as per MDACC policy for study subjects.
- •Females must be surgically or biologically sterile or if of childbearing potential, must have a negative serum or urine pregnancy test within 72 hours before the start of the treatment and each subsequent dose.
- •Women of childbearing potential must agree to use an adequate method of contraception during the study and until 4 months after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 1 month after the last treatment
- •Males need to inform the doctor right away if the partner becomes pregnant or suspects pregnancy. While in this study and for 30 days after the last treatment the patient should not donate sperm for the purposes of reproduction. He will need to use a condom while in this study and for 30 days after the last treatment
排除标准
- •Allergy to azacitidine or pembrolizumab or the drugs' components
- •Active and uncontrolled comorbidities including active uncontrolled infection, uncontrolled hypertension despite adequate medical therapy, active and uncontrolled congestive heart failure New York Heart Association (NYHA) class III/IV, clinically significant and uncontrolled arrhythmia as judged by the treating physician
- •Patients with known infection with human immunodeficiency virus (HIV) or active Hepatitis B or C
- •Any other medical, psychological, or social condition that may interfere with study participation or compliance, or compromise patient safety in the opinion of the investigator
- •Pregnant or breastfeeding
- •Has received a live vaccine within 30 days of planned start study therapy
- •Current or prior use of immunosuppressive medication within 14 days prior to the first dose of pembrolizumab.
- •The following are exceptions to this criterion:
- •Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)
- •Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent
- •Steroids as premedication for hypersensitivity reactions (eg, computed tomography [CT] scan premedication)
- •As per Inclusion criteria #2
- •Active or prior documented autoimmune disease (including inflammatory bowel disease, celiac disease, Wegener syndrome) within the past 2 years. Subjects with childhood atopy or asthma, vitiligo, alopecia, Hashimoto syndrome, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded
- •Has known active central nervous system metastases and/or carcinomatous meningitis
研究组 & 干预措施
Pembrolizumab plus Azacitidine
Experimental
Pembrolizumab by vein over about 30 minutes every 3 weeks. Azacitidine by vein over about 60-90 minutes on Days 1-7 of each 28-day study cycle
干预措施: Azacytidine (Drug)
Pembrolizumab plus Azacitidine
Experimental
Pembrolizumab by vein over about 30 minutes every 3 weeks. Azacitidine by vein over about 60-90 minutes on Days 1-7 of each 28-day study cycle
干预措施: Pembrolizumab (Drug)
结局指标
主要结局
To assess the overall response rate (ORR)
时间窗: through study completion, an average of 1 year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Efficacy and Safety of Azacitidine Combined With Interferon in the Treatment of Post-transplant RecurrenceHSCTEfficacy and SafetyNCT04078399Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine30
已完成
1 期
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML)Adult Acute Myeloblastic LeukemiaNCT00890929Stanford University45
Unknown
2 期
Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction TherapyElderlyAcute Myeloid LeukemiaNCT00728520Kansas City Veteran Affairs Medical Center40
已完成
2 期
Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic SyndromeMyelodysplastic Syndrome (MDS)NCT01599325Celgene72
进行中（未招募）
2 期
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)Chronic Myeloid LeukemiaNCT05768711Groupe Francophone des Myelodysplasies44